Douglas W. Pagan - 16 Apr 2026 Form 4 Insider Report for Kailera Therapeutics, Inc. (KLRA)

Reporting relationship: Chief Financial Officer
Issuer ticker: KLRA
Reported as of: 16 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Apr 2026, 17:01:51 UTC
Prior SEC filing: 29 Dec 2021
Source filing: View source filing
Reporting owner signature: /s/ John Mei, Attorney-in-fact

Key filing fact

Douglas W. Pagan filed Form 4 for Kailera Therapeutics, Inc. (KLRA) on 20 Apr 2026.

Key facts

This page summarizes Douglas W. Pagan's Form 4 filing for Kailera Therapeutics, Inc. (KLRA).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 20 Apr 2026, 17:01.

Change

Previous filing in this sequence was filed on 29 Dec 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001628880 Primary reporting owner

Pagan Douglas W.

Relationship: Chief Financial Officer
Address: C/O KAILERA THERAPEUTICS, INC., 180 THIRD AVENUE, 4TH FLOOR, WALTHAM
Signature: /s/ John Mei, Attorney-in-fact
Signature date: 20 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KLRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 16 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $16.00
Footnotes: F1

KLRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +100,000
Change %
Price: $0.000000^*
Shares after: 100,000
Date: 16 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $16.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.

Footnote F2

The options vest and become exercisable, if at all, as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the "Performance Measurement Period"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date.